On February 17, 2026, Acorn Capital Advisors reported the sale of 225,000 shares of Terns Pharmaceuticals (NASDAQ:TERN)an estimated trade of $5.20 million based on the quarterly average price.
According to a filing with the Securities and Exchange Commission on February 17, 2026, Acorn Capital Advisors reduced its position in Terns Pharmaceuticals (NASDAQ:TERN) for 225,000 shares during the fourth quarter of 2025. The estimated value of the transaction was approximately $5.20 million, calculated using the average closing price for the quarter. The quarter-end value of the remaining stake reflected changes in market valuation.
-
Acorn Capital Advisors’ Terns Pharmaceuticals stake now represents approximately 24% of its 13F AUM after the recent sale.
-
Main participations after the presentation:
-
NASDAQ: TERM: $70.55 million (23.9% of assets under management)
-
NASDAQ:CGON: $46.98 million (15.9% of assets under management)
-
NASDAQ:URGN: $33.92 million (11.5% of assets under management)
-
NASDAQ:TRVI: $26.85 million (9.1% of assets under management)
-
NASDAQ:PBYI: $24.58 million (8.3% of assets under management)
-
-
As of Monday, Terns Pharmaceuticals shares were priced at $50.08, up a staggering 1,400% from last year and significantly outpacing the S&P 500’s roughly 15% gain in the same period.
|
Metric |
Worth |
|---|---|
|
Price (as of Monday) |
$50.08 |
|
Market capitalization |
5.5 billion dollars |
|
Net Income (TTM) |
($94.44 million) |
-
Terns Pharmaceuticals develops clinical-stage small molecule therapies targeting nonalcoholic steatohepatitis (NASH) and obesity, with lead candidates including TERN-101, TERN-201, TERN-501 and TERN-601.
-
The firm operates a research-driven business model focused on advancing patented drug candidates through clinical trials, with future revenue anticipated from successful commercialization and potential partnerships.
-
It is targeted at healthcare providers, biopharmaceutical partners, and patients affected by NASH and metabolic diseases, primarily in the United States and global markets.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for NASH and metabolic disorders. With a portfolio focused on differentiated small molecule drug candidates, the company leverages advanced clinical research and development capabilities to address important unmet medical needs. Its strategy focuses on advancing proprietary compounds through clinical milestones to establish a competitive position in the biotechnology sector.
Terns has excelled in biotech, with shares skyrocketing around 1,400% in just one year. That’s the kind of spectacular profit that can usually trigger some repositioning among investors, even those who still believe in the company’s future. And in this case, even after the reduction, Terns remains the fund’s largest holding, representing almost a quarter of its assets, which is certainly an indication of strong conviction rather than a pullback.
Operationally, Terns has pivoted to focus on oncology, with promising early efficacy and safety results in the treatment of chronic myeloid leukemia. Additionally, the company ended the year with around $1 billion in cash, providing runway extending into 2031 and the flexibility to move toward pivotal testing. That setup has helped the stock continue its ascent since the end of last quarter, rising about 25%.
Ultimately, in this portfolio, Terns stands out among other high-conviction biotech investments and reinforces a strategy that favors asymmetric outcomes over mere diversification.